Navigation Links
Bowman Perfusion Monitor

ProductsBowman Perfusion Monitor
Company Hemedex, Inc.
Item Bowman Perfusion Monitor
Features Absolute, real-time continuous perfusion measured from 0 to 200 ml/100g-min. Works with the QFlow 500 Thermal Diffusion Probe (TDP) - a minimally invasive (<1 mm diameter) flexible, interstitial catheter. 6.4 inch TFT display. Programmable visual/audio alarm. User-friendly interface with five easy-to-use buttons. Built in printer. IV pole mountable.
Description The Bowman Perfusion Monitor runs continuously and displays perfusion data from the previous 1-10 days. In the automatic (autopilot) mode, the monitor periodically performs in situ calibration according to a pre-determined set of rules. The rules may be changed for particular situations. Absolute tissue perfusion, as well as tissue temperature, is displayed graphically as a function of time throughout the measurement sequence. Data files may also be reviewed, and the monitor screens can be printed onsite using the built-in printer.
Info Hemedex, Inc.
Customer Service: (866) 436-3339
Web site: http://www.hemedex.com/

Related medicine products :

1. Bowman Probe
2. AMINCO-Bowman Series 2 (AB2) Spectrofluorometer
3. Clinitemp Perfusion Monitor Strips
4. Coronary Artery Perfusion Cannulae with Balloon
5. DLP® Coronary Perfusion Adapter, Y-Type
6. DLP® Multiple Perfusion Sets
7. Vision Monitor Visual electrophysiology
8. Metrikas AC1Now Monitor
9. ICP Express Monitoring System
10. Camino MPM-1 Multi-Parameter Monitor
11. Ventrix ICP Monitor
...eoGen surgically implanted bone growth stimulator ... when surgery is already planned or when patient c...s totally surgically implanted, patients are assur...on site 24 hours a day for up to 6 months. , ,...
BIG ADVANTAGE Cannulated Titanium Interference Screws
...rew ACL Interference Screw is indicated for graft ...and PCL reconstructions with bone-patellar tendon-... SmartScrew ACL provides easy and atraumatic inser... type. The unique Self-Reinforced 96L/4D copolymer...
ADVANTAGE Titanium Cannulated Interference Screws
Medicine Products:
(Date:11/24/2009)...RNewswire/--Nextmonth,UnitedHealthcarewilloffertwo...c-AmericanseniorsunderstandthebasicsofMedicare.Fol...mba®Goldclass,aLatin-infusedfitnessprogramtha...tango. ,, UnitedHealthcarewilloffertheseseminar...henlearningabouttheirhealthcareoptions. Therearea...
(Date:11/24/2009)...ewswire/--Bionorica,aninternationalcompanypioneeri...theavailabilityofneweducationalresourcesforparents...eton"StayingNaturallyHealthyduringtheHolidays,"the...onthecompany,swebsiteat www.bionoricausa.com . ,...ntotheNaturalMomstipsheets,withcontentcontributedb...
(Date:11/24/2009)...wire-FirstCall/--HealthSouthCorporation(NYSE: HLS ...MerrillLynch2009CreditConferenceinNewYorkonDec.2-3...surerEdFaywillbespeakingonThursday,Dec.3,2009,at3:...availableat http://investor.healthsouth.com byclic..., HealthSouthisthenation,slargestproviderofinpat...
(Date:11/24/2009)...rd off peripheral artery disease, researchers say...- Among people aged 75 and older, the herbal suppl..., stroke or death, a new study finds. , There i...ht help prevent the leg-circulation problem known ... contains nutrients called flavonoids, which are a...
(Date:11/24/2009)...art prospects, but cancer risk remains , ...y offers yet more proof that smoking is a major ri... , Researchers followed 12,152 American and Eur... nonsmokers for three years. During that time, cur... cancer, 2.26 times more likely to die of heart di...
Breaking Medicine News(10 mins):Health News:UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program 2Health News:Bionorica Offers Expert Resources, Health Tips for 'Natural Moms' 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3Health News:Smokers Double Their Risk for Heart Disease 2
...leep Loss Costs Economy up to $15 Billion Each Yea...S, March 30 Now more than ever, Americans need th...of the first things people scrimp on when time is ...p in America poll by the National Sleep Foundation...
...nhancements maximize and automate physician practi...ain financial edge during economic downturn , , ...ding developer of healthcare software solutions fo...ca,s award-winning Electronic Health Record (EHR) ...
... , , , - Lorcaserin Very Well Tolerated Througho... for Today at 8:30 a.m. EDT , , SAN DIEGO, March...ARNA ) announced today positive top-line results f...ficacy of lorcaserin for weight management. Statis...
...INCINNATI, March 30 LCA-Vision Inc. (Nasdaq: LC...n services under the Lasik Plus (R) brand, today a...g with the Securities and Exchange Commission, the... Additionally, the Joffe Group stated that it has...
...ompany also Introduces Everest Award for Hospitals... , ANN ARBOR, Mich., March 30 The Healthcare bus... study identifying the 100 top U.S. hospitals base...Hospitals National Balanced Scorecard that evaluat...
...orld-renowned neurosurgeon for over 40 years, Dr. ...body and spirit are essential for optimum health. ...Ft. Wayne, Indiana, Rudy Kachmann, M.D., creator o...s. Now, having retained award-winning TransMedia G...
Other Medicine News:Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:iMedica Corporation Announces the Release of Patient Relationship Manager 2009 2Health News:iMedica Corporation Announces the Release of Patient Relationship Manager 2009 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 2Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 4Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 5Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 6Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 7Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 8Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 9Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 10Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 11Health News:LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees 2Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 2Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 3Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 4Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 5Health News:Dr. Rudy Kachmann, Neurosurgeon, Author, Lecturer & Founder of Kachmann Mind Body Institute Selects TransMedia Group as Agency of Record 2
(Date:11/24/2009)...ov.24/PRNewswire/--ZargisMedicalCorp.,asubsidiaryo...sCorporateResearch(NYSE: SI ),todayannouncedthatit...2009episodeofCBS, TheEarlyShow duringasegmentinwhi...eviewedfivewinningproductsfromthepublication,s2009...dely-viewedtelevisionmorningnewstalkshowbroadcastb...
(Date:11/24/2009)...PRNewswire/--AmbitBiosciencesCorporationannouncedt...AC220,anovelsecondgenerationFLT3inhibitor,inAMLatt...)tobeheldinNewOrleans,LA,December5-8,2009.Anoralpr...lPhaseImonotherapysafetystudyinadultswithacutemyel...bepresentedevaluatingtheeffectofAC220monotherapyan...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--EchoTherapeutics,Inc....e-freeSymphony(TM)tCGMSystemasanon-invasive,wirele...temanditsPrelude(TM)SkinPrepSystemfortransdermaldr...ChairmanandChiefExecutiveOfficer,willpresentatthe1...nce,sponsoredbytheNewYorkSocietyofSecuritiesAnalys...
Breaking Medicine Technology:Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 1Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 1YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 2YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 4Beckman Coulter Announces Third Quarter 2009 Results 5858 1Beckman Coulter Announces Third Quarter 2009 Results 5858 2Beckman Coulter Announces Third Quarter 2009 Results 5858 3Beckman Coulter Announces Third Quarter 2009 Results 5858 4Beckman Coulter Announces Third Quarter 2009 Results 5858 5Beckman Coulter Announces Third Quarter 2009 Results 5858 6Beckman Coulter Announces Third Quarter 2009 Results 5858 7Beckman Coulter Announces Third Quarter 2009 Results 5858 8Beckman Coulter Announces Third Quarter 2009 Results 5858 9Beckman Coulter Announces Third Quarter 2009 Results 5858 10Beckman Coulter Announces Third Quarter 2009 Results 5858 11Beckman Coulter Announces Third Quarter 2009 Results 5858 12Beckman Coulter Announces Third Quarter 2009 Results 5858 13Beckman Coulter Announces Third Quarter 2009 Results 5858 14Beckman Coulter Announces Third Quarter 2009 Results 5858 15Beckman Coulter Announces Third Quarter 2009 Results 5858 16Beckman Coulter Announces Third Quarter 2009 Results 5858 17Beckman Coulter Announces Third Quarter 2009 Results 5858 18Beckman Coulter Announces Third Quarter 2009 Results 5858 19Beckman Coulter Announces Third Quarter 2009 Results 5858 20Beckman Coulter Announces Third Quarter 2009 Results 5858 21Beckman Coulter Announces Third Quarter 2009 Results 5858 22Beckman Coulter Announces Third Quarter 2009 Results 5858 23Beckman Coulter Announces Third Quarter 2009 Results 5858 24Beckman Coulter Announces Third Quarter 2009 Results 5858 25Beckman Coulter Announces Third Quarter 2009 Results 5858 26Beckman Coulter Announces Third Quarter 2009 Results 5858 27Beckman Coulter Announces Third Quarter 2009 Results 5858 28Beckman Coulter Announces Third Quarter 2009 Results 5858 29Beckman Coulter Announces Third Quarter 2009 Results 5858 30Beckman Coulter Announces Third Quarter 2009 Results 5858 31Beckman Coulter Announces Third Quarter 2009 Results 5858 32Beckman Coulter Announces Third Quarter 2009 Results 5858 33Beckman Coulter Announces Third Quarter 2009 Results 5858 34Beckman Coulter Announces Third Quarter 2009 Results 5858 35